Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024
23. Mai 2024 17:00 ET
|
Tizona Therapeutics Inc
TTX-080 plus EGFR Inhibitor Cetuximab Demonstrated Promising Evidence of Clinical Activity in Patients with Biomarker-Defined Metastatic Colorectal Cancer and Locally Advanced/Metastatic Head and Neck...